7 Recruiting Studies Using Camizestrant
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Camizestrant
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
📍 Research Site — Dothan, Alabama
Breast Cancer, Early Breast Cancer
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
📍 Research Site — Boston, Massachusetts
Ovarian Cancer
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
📍 Research Site — St Louis, Missouri
ER+ HER2- Advanced Breast Cancer
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
📍 Research Site — St Louis, Missouri
Advanced Breast Cancer
View Study & Checklist ➔ 🟢 Recruiting Phase3 💊 Investigational Drug / Biologic
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
📍 Research Site — Birmingham, Alabama
Breast Cancer, Early Breast Cancer
View Study & Checklist ➔ 🟢 Recruiting Phase3 💊 Investigational Drug / Biologic
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
📍 Research Site — Duarte, California
ER-Positive HER2-Negative Breast Cancer
View Study & Checklist ➔ 🟢 Recruiting Phase3 💊 Investigational Drug / Biologic
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
📍 Research Site — Gilbert, Arizona
Advanced Breast Cancer
View Study & Checklist ➔